テルミサルタンの世界市場

テルミサルタンの世界市場は2030年までに48億米ドルに達する

2024年に41億米ドルと推定されるテルミサルタンの世界市場は、2024年から2030年にかけてCAGR 2.9%で成長し、2030年には48億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである単一組成テルミサルタンは、CAGR 3.5%を記録し、分析期間終了時には33億米ドルに達すると予測されます。コンビネーションテルミサルタン分野の成長率は、分析期間中CAGR 1.5%と推定されます。

米国市場は11億米ドル、中国はCAGR 5.6％で成長予測

米国のテルミサルタン市場は、2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9億4,800万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.2％と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界のテルミサルタン市場- 主要動向と促進要因のまとめ

テルミサルタンが高血圧および心血管リスク管理において広く処方されている理由とは？

アンジオテンシンII受容体拮抗薬（ARB）であるテルミサルタンは、高血圧治療および高リスク患者の心血管リスク軽減のための最前線の薬剤です。アンジオテンシンII受容体を選択的に阻害することにより、テルミサルタンは血管拡張を促進し、アルドステロン活性を低下させ、ACE阻害剤に伴う持続的な咳を伴わずに血圧を低下させます。半減期が長く、1日1回の服用でコンプライアンスが向上するため、慢性疾患の管理に適した薬剤です。

高血圧以外にも、テルミサルタンは高リスクのアテローム性動脈硬化性疾患患者における心筋梗塞、脳卒中、心血管死のリスク軽減にも承認されています。内皮機能、インスリン感受性および動脈硬化を改善するその能力は、メタボリックシンドロームおよび2型糖尿病患者における使用の幅を広げています。このような治療プロファイルの拡大は、心血管治療における併存疾患への対処を目指す処方者の間での持続的な需要の一因となっています。

ジェネリック医薬品の普及と合剤は、市場参入性と市場規模をどのように牽引しているか？

主要市場で特許が満了した後、テルミサルタンではジェネリック医薬品の普及が著しく、特に高血圧の有病率が増加している新興国において、購入しやすい価格と市場へのアクセス性が向上しています。生物学的に同等なジェネリック医薬品が入手可能になったことで、各国のフォーミュラーや保険プロバイダーはテルミサルタンを費用対効果の高い治療選択肢として掲載することが可能になり、公的・私的医療環境の両方においてテルミサルタンの処方数がさらに増加しています。

テルミサルタンと他の降圧剤（ヒドロクロロチアジド、アムロジピン、メトプロロールなど）との合剤（FDC）は、その相乗効果と服薬アドヒアランスの簡略化により、臨床的に人気を集めています。これらの併用療法は、血圧目標を達成するために多剤併用レジメンを必要とする患者にとって特に有益です。製薬メーカーは、製品ポートフォリオを差別化し、慢性期医療における長期的なアドヒアランス戦略をサポートするために、FDCのフォーマットを活用しています。

持続的な需要に貢献している患者層と地域市場は？

高血圧、心血管疾患、糖尿病の世界の増加は、特に高齢化した集団や複数の危険因子を持つ患者におけるテルミサルタンの需要を促進しています。メタボリックシンドロームの中高年、脳卒中や心筋梗塞の既往歴のある人、新たに高血圧と診断された患者は、主要なユーザーグループです。テルミサルタンの腎保護作用は、早期腎症の糖尿病患者にも適しています。

地域的には、アジア太平洋とラテンアメリカが、ヘルスケアインフラの拡大、診断率の上昇、非感染性疾患の高い有病率により、力強い市場成長を目の当たりにしています。特にインドと中国は、国内の製造能力と公的医療支出の増加に支えられ、ジェネリック医薬品の主要な消費地となっています。対照的に、北米と欧州は成熟した市場であり、FDCの革新と治療法の転換が成長の鍵を握っています。

臨床ガイドライン、競合価格、サプライチェーンの機敏性は市場力学にどのような影響を与えているか？

テルミサルタンは、米国心臓協会（AHA）、欧州高血圧学会（ESH）、WHOなどの世界の臨床ガイドラインで強く推奨されており、降圧治療における最前線の役割を強化しています。その安全性プロファイル、代謝改善効果、忍容性は、特にACE阻害薬に不耐性の患者を対象としたアルゴリズムに基づく高血圧管理への継続的な組み入れを支持しています。

しかし、ジェネリック医薬品の競争は激化しており、メーカー各社は、生産効率の最適化、付加価値の高い製剤による差別化、地域展開の拡大を迫られています。サプライチェーンの強靭性-特に原薬の調達と規制遵守-は、価格に敏感な市場や規制の厳しい市場で事業を展開する製薬企業の戦略的優先事項であり続けています。世界的に需要パターンが変化する中で市場シェアを維持するには、現地の流通業者や公衆衛生調達プログラムとの提携が鍵となります。

テルミサルタン市場の成長を促進する要因は何か？

テルミサルタン市場は、世界の高血圧有病率の上昇、FDCの採用拡大、マルチリスク心血管系患者における良好な有効性・安全性プロファイルにより、着実に拡大しています。慢性疾患の負担が増大し、医療制度が費用対効果の高い一次予防戦略を優先する中、テルミサルタンは多様な患者集団や地域にわたって幅広い治療有用性を提供し続けています。

今後の市場成長は、メーカーが価格設定の制約、規制への対応、組み合わせやライフサイクル延長戦略による治療イノベーションをいかに効果的に進めるかにかかっています。競合情勢やアウトカム重視の世界の医薬品市場において、競合情勢が高血圧ガイドラインの進化や新たな心血管治療薬の出現の中で、競合情勢がその役割を維持できるかどうかが、その継続的な存在意義を決定することになるであろう。

セグメント

組成（単剤、配合剤）;適応症（高血圧症、腎症、肝腎症候群、心停止、脳卒中）;剤形（錠剤、カプセル剤、注射剤、経口懸濁剤）;販売チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の42社）

• Abbott Laboratories
• Akums Drugs and Pharmaceuticals
• Alembic Pharmaceuticals Ltd.
• Aurobindo Pharma Ltd.
• Boehringer Ingelheim GmbH
• Cadila Healthcare Ltd.（Zydus Cadila）
• Cipla Ltd.
• CTX Lifesciences Pvt. Ltd.
• Glenmark Pharmaceuticals Ltd.
• Hetero Drugs Ltd.
• Lupin Ltd.
• Mylan N.V.（Viatris Inc.）
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Smilax Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Unichem Laboratories Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Telmisartan Market to Reach US$4.8 Billion by 2030

The global market for Telmisartan estimated at US$4.1 Billion in the year 2024, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Single Composition Telmisartan, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Combinational Telmisartan segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 5.6% CAGR

The Telmisartan market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$948.0 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Telmisartan Market - Key Trends & Drivers Summarized

Why Is Telmisartan a Widely Prescribed Therapeutic in Hypertension and Cardiovascular Risk Management?

Telmisartan, an angiotensin II receptor blocker (ARB), is a frontline medication for the treatment of hypertension and cardiovascular risk reduction in high-risk patients. By selectively inhibiting angiotensin II receptors, telmisartan promotes vasodilation, reduces aldosterone activity, and decreases blood pressure without the persistent cough associated with ACE inhibitors. Its long half-life and once-daily dosing enhance compliance, making it a preferred option for chronic disease management.

Beyond hypertension, telmisartan is approved for reducing the risk of myocardial infarction, stroke, and cardiovascular death in patients with high-risk atherosclerotic disease. Its ability to improve endothelial function, insulin sensitivity, and arterial stiffness has broadened its use in metabolic syndrome and type 2 diabetes patients. This expanded therapeutic profile has contributed to its sustained demand among prescribers aiming to address comorbidities in cardiovascular care.

How Are Generic Penetration and Fixed-Dose Combinations Driving Market Accessibility and Volume?

Following patent expiries in major markets, telmisartan has seen significant generic penetration, which has improved affordability and market accessibility, particularly in developing countries with growing hypertension prevalence. The availability of bioequivalent generics has enabled national formularies and insurance providers to list telmisartan as a cost-effective treatment option, further driving its prescription volume in both public and private healthcare settings.

Fixed-dose combinations (FDCs) of telmisartan with other antihypertensive agents-such as hydrochlorothiazide, amlodipine, and metoprolol-are gaining clinical favor due to their synergistic efficacy and simplified adherence. These combination therapies are particularly beneficial for patients requiring multi-drug regimens to achieve blood pressure targets. Pharmaceutical manufacturers are leveraging FDC formats to differentiate their product portfolios and support long-term adherence strategies in chronic care.

Which Patient Demographics and Regional Markets Are Contributing to Sustained Demand?

The global rise in hypertension, cardiovascular disease, and diabetes is fueling demand for telmisartan, particularly among aging populations and patients with multiple risk factors. Middle-aged adults with metabolic syndrome, individuals with a history of stroke or myocardial infarction, and newly diagnosed hypertensive patients represent key user groups. Telmisartan’s renal protective effects also make it suitable for diabetic patients with early-stage nephropathy.

Regionally, Asia-Pacific and Latin America are witnessing strong market growth due to expanding healthcare infrastructure, increased diagnosis rates, and high prevalence of non-communicable diseases. India and China, in particular, are major consumption hubs for telmisartan generics, supported by domestic manufacturing capacity and rising public health expenditure. In contrast, North America and Europe represent mature markets where FDC innovation and therapeutic switching are key growth levers.

How Are Clinical Guidelines, Competitive Pricing, and Supply Chain Agility Influencing Market Dynamics?

Telmisartan is strongly recommended by global clinical guidelines, including those from the American Heart Association (AHA), European Society of Hypertension (ESH), and WHO, reinforcing its frontline role in antihypertensive therapy. Its safety profile, metabolic benefits, and tolerability support its continued inclusion in algorithm-based hypertension management, particularly for patients intolerant to ACE inhibitors.

However, intense competition in the generic space is exerting pricing pressure, prompting manufacturers to optimize production efficiency, differentiate through value-added formulations, and expand regional reach. Supply chain resilience-especially in terms of API sourcing and regulatory compliance-remains a strategic priority for pharmaceutical companies operating in price-sensitive or tightly regulated markets. Partnerships with local distributors and public health procurement programs are key to maintaining market share amid shifting global demand patterns.

What Are the Factors Driving Growth in the Telmisartan Market?

The telmisartan market is expanding steadily due to rising global hypertension prevalence, growing adoption of FDCs, and its favorable efficacy-safety profile in multi-risk cardiovascular patients. As chronic disease burdens mount and healthcare systems prioritize cost-effective primary prevention strategies, telmisartan continues to offer broad therapeutic utility across diverse patient populations and geographies.

Looking forward, market growth will depend on how effectively manufacturers navigate pricing constraints, regulatory compliance, and therapeutic innovation through combinations and lifecycle extension strategies. Whether telmisartan can maintain its role amid evolving hypertension guidelines and emerging cardiovascular therapies will define its continued relevance in a competitive and outcomes-driven global pharmaceutical landscape.

SCOPE OF STUDY:

The report analyzes the Telmisartan market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Composition (Single, Combinational); Indication (Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest, Stroke); Dosage Form (Tablets, Capsules, Injection, Oral Suspension); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Akums Drugs and Pharmaceuticals
• Alembic Pharmaceuticals Ltd.
• Aurobindo Pharma Ltd.
• Boehringer Ingelheim GmbH
• Cadila Healthcare Ltd. (Zydus Cadila)
• Cipla Ltd.
• CTX Lifesciences Pvt. Ltd.
• Glenmark Pharmaceuticals Ltd.
• Hetero Drugs Ltd.
• Lupin Ltd.
• Mylan N.V. (Viatris Inc.)
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Smilax Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Unichem Laboratories Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Telmisartan - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Telmisartan Maintains Core Role in First-Line Management of Hypertension and Cardiovascular Risk
  • Dual Mechanism as ARB and PPAR-? Agonist Enhances Appeal in Metabolic Syndrome and Diabetes Cohorts
  • Extensive Generic Competition Ensures Accessibility and High Volume in Global Prescribing Patterns
  • Emerging Research Supports Use in Proteinuria and Early-Stage Nephropathy Beyond BP Control
  • Growing Demand for Once-Daily, High Bioavailability Antihypertensives Drives Telmisartan Preference
  • Pharmacovigilance Data Highlights Strong Tolerability and Safety Profile in Long-Term Use
  • Physician Adoption Driven by Favorable Outcomes in Cardiovascular Event Reduction Studies
  • Extended Release and Fixed-Dose Combinations Gain Ground in Market Differentiation Strategies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Telmisartan Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Telmisartan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Telmisartan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Telmisartan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Single by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Single by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Single by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Combinational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Combinational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Combinational by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Oral Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Oral Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Oral Suspension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Tablets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Capsules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Hypertension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Nephropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Nephropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Nephropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hepatorenal Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hepatorenal Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hepatorenal Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Cardiac Arrest by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Cardiac Arrest by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Cardiac Arrest by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Stroke by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• JAPAN
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• CHINA
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 83: China Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• EUROPE
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Telmisartan by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Telmisartan by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Telmisartan by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• FRANCE
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 110: France Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• GERMANY
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 146: UK Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Telmisartan by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Telmisartan by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Telmisartan by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• INDIA
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 221: India Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Telmisartan by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Telmisartan by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Telmisartan by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Telmisartan by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Telmisartan by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Telmisartan by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030
• AFRICA
  • Telmisartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Telmisartan by Composition - Single and Combinational - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Telmisartan by Composition - Single and Combinational Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Telmisartan by Composition - Percentage Breakdown of Value Sales for Single and Combinational for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Telmisartan by Dosage Form - Injection, Oral Suspension, Tablets and Capsules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Telmisartan by Dosage Form - Percentage Breakdown of Value Sales for Injection, Oral Suspension, Tablets and Capsules for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Telmisartan by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Telmisartan by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Telmisartan by Indication - Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Telmisartan by Indication - Percentage Breakdown of Value Sales for Hypertension, Nephropathy, Hepatorenal Syndrome, Cardiac Arrest and Stroke for the Years 2015, 2025 & 2030

IV. COMPETITION